Form 8-K - Current report:
SEC Accession No. 0001737287-20-000064
Filing Date
2020-12-15
Accepted
2020-12-15 08:32:23
Documents
14
Period of Report
2020-12-14
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K allo-20201214.htm   iXBRL 8-K 39508
  Complete submission text file 0001737287-20-000064.txt   182670

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20201214.xsd EX-101.SCH 2411
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20201214_cal.xml EX-101.CAL 702
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20201214_def.xml EX-101.DEF 1635
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20201214_lab.xml EX-101.LAB 24270
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20201214_pre.xml EX-101.PRE 12638
7 EXTRACTED XBRL INSTANCE DOCUMENT allo-20201214_htm.xml XML 10808
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 201388266
SIC: 2836 Biological Products, (No Diagnostic Substances)